Results 91 to 100 of about 571,282 (185)

Immunohistochemistry as a tool for identifying PDGFRA amplification in central nervous system tumors

Brain Pathology, EarlyView.
PDGFRA gene amplification is now recognized as a diagnostically and prognostically relevant molecular alteration in central nervous system tumors. Herein, we demonstrated that PDGFRA immunohistochemistry is a highly specific and sensitive biomarker for identifying PDGFRA amplification and should be part of the neuropathologist's routine panel of ...
Arnault Tauziède‐Espariat, Guilhem Amargos, Farah Sassi, Lauren Hasty, Alice Métais, Pascale Varlet   +5 more
wiley   +1 more source

Combination of MRI-based prediction and CRISPR/Cas12a-based detection for IDH genotyping in glioma

npj Precision Oncology
Early identification of IDH mutation status is of great significance in clinical therapeutic decision-making in the treatment of glioma. We demonstrate a technological solution to improve the accuracy and reliability of IDH mutation detection by ...
Donghu Yu, Qisheng Zhong, Yilei Xiao, Zhebin Feng, Feng Tang, Shiyu Feng, Yuxiang Cai, Yutong Gao, Tian Lan, Mingjun Li, Fuhua Yu, Zefen Wang, Xu Gao, Zhiqiang Li   +13 more
doaj   +1 more source

PTEN homozygous deletion is a negative prognostic factor in tumor treating fields‐treated glioblastoma, IDH wildtype patients

Brain Pathology, EarlyView.
In a molecularly confirmed cohort of 64 newly diagnosed, TTFields‐treated glioblastomas, IDH‐wildtype, homozygous PTEN deletion was associated with markedly shorter overall survival (368 vs. 603 days) and remained an independent adverse prognostic factor.
Jakob Nückles, Claudius Jelgersma, Christin Siewert, Brendan Osberg, Simone Schmid, Arend Koch, Eilís Perez, Daniel Teichmann, Martin Misch, Anna‐Gila Karbe, Susanne Ukrow, Patrick N. Harter, Ruth M. Stassart, Peter Vajkoczy, Julia Onken, David Capper   +15 more
wiley   +1 more source

Gliomas with pleomorphic and pseudopapillary features (GPAP) are circumscribed tumors with targetable mutations, prolonged survival, and frequent tumor predisposition

Brain Pathology, EarlyView.
DNA methylation profiling identifies GPAP as a distinct circumscribed glioma with a characteristic expansive, multicystic radiological appearance, pleomorphic and pseudopapillary histology, a recognizable CNV profile, druggable molecular alterations, and recurrent cancer predisposition syndromes.
Alberto Picca, Valeria Barresi, Aude Trinquet, Luca Bertero, Lucia Nichelli, Guillaume Chotard, Michèle Bernier, Thomas Gareau, Salah Eddine Oussama Kacimi, Jaydutt Bhalshankar, Mathilde Filser, Julien Masliah‐Planchon, Marta Iollo, Henri Malaize, Bertrand Mathon, Luc Bauchet, Kifah Khouri, Besma Barka, Hélène Madry, Sabrina Rossi, Evelina Miele, Giuseppe Kenneth Ricciardi, Catherine Carpentier, Irina Coin, Marc Sanson, Mehdi Touat, Caroline Dehais, Alessia Pellerino, Roberta Rudà, Paola Cassoni, Valérie Rigau, Emmanuelle Uro‐Coste, Karima Mokhtari, Ahmed Idbaih, Patrick R. Benusiglio, Franck Bielle   +35 more
wiley   +1 more source

Common pathways and outliers in glucose catabolism across Trypanosomatidae

The FEBS Journal, EarlyView.
Trypanosomatid parasites, including Trypanosoma sp., Leishmania sp., Phytomonas sp., and Vickermania sp., share a common motif: a metabolism built around the glycosome, a unique peroxisome‐derived organelle housing the first steps of glycolysis. Yet, these organisms have evolved remarkably diverse strategies to catabolize glucose, excreting distinct ...
Fred R. Opperdoes, Mayke B. Alencar, Ariel M. Silber, Ingrid Škodová‐Sveráková, Kristína Záhonová, Vyacheslav Yurchenko   +5 more
wiley   +1 more source

Reply to Zaragori et al.: “Is IDH mutation status associated with 18F-FDopa PET uptake”

, 2020
We thank Zaragori et al. for reading and commenting on our article regarding the lack of correlation between 3,4‐dihydroxy‐6‐[18F]‐fluoro-L‐phenylalanine (F-DOPA) uptake parameters and IDH mutation status and 1p/19q co-deletion in glioma.
Minniti G., Carideo L., Cicone F., Scaringi C.   +3 more
core   +1 more source

Isocitrate Dehydrogenase (IDH) Mutations in Hematological Malignancies: Epidemiology, Mechanisms, and Therapeutic Strategies

MedComm – Future Medicine
Isocitrate dehydrogenase (IDH) mutation is an important molecular abnormality in hematological malignancies, occurring widely in various disease types such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (
Jinkun Xu, Haiying Bai, Lijuan Hu
doaj   +1 more source

Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas

OncoImmunology, 2018
Background: Mutations in isocitrate dehydrogenase (IDH) affect the development and prognosis of gliomas. We investigated the role of IDH mutations in the regulation of immune phenotype in lower-grade gliomas (LGGs).Method and patients: A total of 1,008 ...
Zenghui Qian, Yiming Li, Xing Fan, Chuanbao Zhang, Yinyan Wang, Tao Jiang, Xing Liu   +6 more
doaj   +1 more source

The PRIME trial: An investigator‐initiated, multicentre, phase II study of the poly(ADP‐ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)‐mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes

British Journal of Haematology, EarlyView.
Rory M. Shallis, Jennifer VanOudenhove, Namrata Chandhok, Justin Watts, Deepa Jeyakumar, Daniel R. Reed, Jan Phillip Bewersdorf, Diane Durecki, Scott Boerner, Richard F. Little, Steven D. Gore, Jing Li, Xun Bao, Li Chen, Sayak Ghatak, Thomas Prebet, Ranjit S. Bindra, Amer M. Zeidan, Stephanie Halene   +18 more
wiley   +1 more source

Myelodysplasia‐Related Gene Mutation Burden Is Associated With Complete Remission After Induction Therapy in Acute Myeloid Leukemia, Not Otherwise Specified: Reclassification According to the Updated Classifications

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Updated classifications incorporating myelodysplasia‐related (MR) gene mutations reclassify many cases previously diagnosed as acute myeloid leukemia, not otherwise specified (AML, NOS). We evaluated the clinical significance of MR gene mutation burden, defined by mutation number and variant allele frequency (VAF), in AML, NOS ...
Taegeun Lee, Daehyun Chu, Miyoung Kim, Young‐Uk Cho, Sang‐Hyun Hwang, Je‐Hwan Lee, Yunsuk Choi, Eun‐Ji Choi, Ho Joon Im, Hyery Kim, Seongsoo Jang   +10 more
wiley   +1 more source